Pfizer's Path to Oncology Dominance
Cashu Finance·4 min read

TL;DR
- Pfizer prepares for patent expirations with strategic acquisitions.
- Focus on expanding oncology portfolio to mitigate revenue loss.
- Continued dividend commitment amidst evolving challenges.
The looming patent expirations are certainly a pressing concern for Pfizer, with key products such as the anticoagulant Eliquis and the breast cancer medication Ibrance approaching the brink of market exclusivity loss. An alarming estimate indicates that up to one-third of Pfizer's revenue could be at stake in the coming years, emphasizing the urgency for strategic action. However, Pfizer's management, led by CEO Albert Bourla, has embarked on a proactive path to address this challenge.
Amid these challenges, Pfizer has made concrete strides toward reinforcing its oncology portfolio. The acquisition of Seagen for $43 billion is particularly noteworthy, as it significantly enhances the company’s efforts to develop new cancer treatments. This aligns with its broader strategy to invest heavily in oncology, a sector anticipated to witness substantial growth, estimated to reach a market value of $280 billion by 2035.
A Shift Toward Cancer Treatment Innovations
To bolster its oncology capabilities, Pfizer is committing 40% of its internal research and development budget to the cancer treatment space. This implies a strong focus on delivering eight breakthrough oncology drugs by 2030. Such ambitious goals not only serve to combat loss of revenue from patent expirations but also position Pfizer as a formidable player in an expanding market.
Interestingly, during previous communications, Bourla has signaled confidence in navigating these turbulent waters, suggesting a shift toward positive revenue growth beginning in 2029. This perspective is rooted in their diversified development and acquisition strategies, particularly related to cancer therapies.

